Sirolimus in Preventing Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ, Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, or Atypical Ductal Hyperplasia

Inclusion Criteria

• Confirmed menopausal status; all patients who have NOT had a prior bilateral oophorectomy and/or are younger than age 60, will require menopausal status verified by follicle stimulating hormone (FSH) and estradiol local labs
• Women diagnosed with DCIS, LCIS, ALH or ADH lesions detected by pathology
• Women scheduled for mastectomy or lumpectomy after DCIS, LCIS, ALH or ADH diagnosis
• Women of child-bearing potential willing to practice 2 forms of contraception, one of which must be a barrier method until at least 30 days after the last dose of rapamycin
• Women of child-bearing potential must have a negative serum pregnancy test at time of enrollment
• Patients must be able to swallow and retain oral medication
• All patients must have given signed, informed consent prior to registration on study
• Leukocytes >= 3,000/uL
• Absolute neutrophil count >= 1,500/uL
• Platelets >= 100,000/uL
• Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) =< 2.5 x ULN
• Total bilirubin (bili) =< 1.5 x ULN or direct bili =< 1 x ULN

Exclusion Criteria

• Women who are pregnant
• Women who are receiving any other concomitant treatment for their DCIS, LCIS, ALH or ADH
• Women who are taking rapamycin for another diagnosis
• Women with an allergy to rapamycin or its derivatives
• Active infection requiring systemic therapy
• Patients who are taking any pills containing herbal (alternative) medicines are NOT eligible for participation; patients must be off any such medications by the time of registration
• Immunocompromised subjects, including patients with human immunodeficiency virus
• Women currently taking strong cytochrome P450 family 3 subfamily A member 4 (CYP3A4) inducers or inhibitors; drugs that cannot be coadministered with rapamycin include but are not limited to: calcium channel blockers: nicardipine, antifungal agents: clotrimazole, fluconazole, antibiotics: troleandomycin, rifapentine, gastrointestinal prokinetic agents: cisapride, metoclopramide, other drugs: bromocriptine, cimetidine, danazol, human immunodeficiency virus (HIV)-protease inhibitors (e.g., ritonavir, indinavir), anticonvulsants: carbamazepine, phenobarbital, phenytoin
• Patients with any of the following conditions or complications are NOT eligible for participation: * Gastrointestinal (GI) tract disease resulting in an inability to take oral medication * Malabsorption syndrome * Require intravenous (IV) alimentation * History of prior surgical procedures affecting absorption * Uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis)